Early detection is a life-saver in most forms of cancer, yet, only 14% of European citizens participate in cancer screening programs. There is an urgent need for accurate, non-invasive, and cost-effective screening tests and their adaption by the public. Colorectal cancer is a disease in which cells in the colon or rectum grow out of control. In the EU, colorectal cancer accounts for about 1 in 8 of all new cancer diagnoses and of all deaths due to cancer. That makes it the second most frequently occurring cancer (after breast cancer) and the second cause of cancer death (after lung cancer).
ONCOSCREEN is focusing on the development of new methods and technologies for colorectal cancer screening and early detection. The project will develop new technologies and methodologies for low-cost colorectal cancer screening and contribute to raising awareness of the disease and its detection. The project consortium comprises 39 partners from 15 EU member states and associated countries. It brings together technical solutions partners, medical professionals, cancer research experts, cancer patient associations, and policymakers.
ONCOSCREEN will employ Healthentia and its mobile app for behavioral data collection from, and guidance of, more than 4,000 patients and citizens across 10 countries. Thus, colorectal cancer will be added to the cervical, ovarian, and pancreatic cancers that Healthentia is already helping manage.
At Innovation Sprint, we will collaborate with clinicians in all ten countries for the definition of the data collection needs to be empowered by Healthentia, as well as with patient organizations for the co-design of the necessary data capturing widgets. We will implement the necessary new Healthentia features stemming from those requirements. Finally, we will integrate with other ONCOSCREEN tools, offering information to the patients and citizens.
Type: HORIZON-RIA, HORIZON-MISS-2021-CANCER-02-01
Duration: 48 months